

Washington University School of Medicine

Digital Commons@Becker

Open Access Publications

12-16-2019

The role of glia in epilepsy, intellectual disability, and other neurodevelopmental disorders in tuberous sclerosis complex

Michael Wong

Washington University School of Medicine in St. Louis

Follow this and additional works at: https://digitalcommons.wustl.edu/open_access_pubs

Please let us know how this document benefits you.

Recommended Citation

Wong, Michael, "The role of glia in epilepsy, intellectual disability, and other neurodevelopmental disorders in tuberous sclerosis complex." *Journal of Neurodevelopmental Disorders*. 11, 1. 30 (2019).
https://digitalcommons.wustl.edu/open_access_pubs/9914

This Open Access Publication is brought to you for free and open access by Digital Commons@Becker. It has been accepted for inclusion in Open Access Publications by an authorized administrator of Digital Commons@Becker. For more information, please contact vanam@wustl.edu.

REVIEW

Open Access



The role of glia in epilepsy, intellectual disability, and other neurodevelopmental disorders in tuberous sclerosis complex

Michael Wong 

Abstract

Background: Tuberous sclerosis complex (TSC) is a genetic disorder characterized by severe neurological manifestations, including epilepsy, intellectual disability, autism, and a range of other behavioral and psychiatric symptoms, collectively referred to as TSC-associated neuropsychiatric disorders (TAND). Various tumors and hamartomas affecting different organs are the pathological hallmarks of the disease, especially cortical tubers of the brain, but specific cellular and molecular abnormalities, such as involving the mechanistic target of rapamycin (mTOR) pathway, have been identified that also cause or contribute to neurological manifestations of TSC independent of gross structural lesions. In particular, while neurons are immediate mediators of neurological symptoms, different types of glial cells have been increasingly recognized to play important roles in the phenotypes of TSC.

Main body: This review summarizes the literature supporting glial dysfunction from both mouse models and clinical studies of TSC. In particular, evidence for the role of astrocytes, microglia, and oligodendrocytes in the pathophysiology of epilepsy and TAND in TSC is analyzed. Therapeutic implications of targeting glia cells in developing novel treatments for the neurological manifestations of TSC are also considered.

Conclusions: Different types of glial cells have both cell autonomous effects and interactions with neurons and other cells that are involved in the pathophysiology of the neurological phenotype of TSC. Targeting glial-mediated mechanisms may represent a novel therapeutic approach for epilepsy and TAND in TSC patients.

Keywords: TAND, Intellectual disability, Autism spectrum disorder, Epilepsy, Tuberous sclerosis, Glia, Astrocyte, Microglia, Oligodendrocyte, White matter

Background

Tuberous sclerosis complex (TSC) is one of the classic neurocutaneous syndromes, featuring characteristic pathological brain and skin lesions, as well as tumors in a number of other organs [1, 2]. With brain involvement, TSC is often characterized by a severe neurodevelopmental disorder, aptly named TSC-associated neuropsychiatric disorders (TAND), including intellectual disability, autism, and other behavioral and psychiatric symptoms [3, 4]. Some degree of cognitive dysfunction, ranging from mild learning disabilities to severe intellectual disability, affects at least 50% of TSC patients.

Similarly, autism spectrum disorder or other behavioral disorders also occur in about half of TSC patients. In addition, epilepsy is extremely common affecting up to 80% of TSC patients, with seizures usually being severe and intractable to treatment and often exacerbating the cognitive and behavioral comorbidities [5].

TSC is caused by mutations in one of two genes, the *TSC1* and *TSC2* genes [1, 2]. These genes encode for two proteins, hamartin (TSC1) and tuberin (TSC2), which bind together to form a protein dimer complex that inhibits the mechanistic target of rapamycin (mTOR) pathway. mTOR is a protein kinase, which serves as a central regulator of a number of important physiological functions, such as cell growth and proliferation, metabolism, and protein synthesis [6, 7]. In TSC, mutation of *TSC1* or *TSC2* leads to a disinhibition or

Correspondence: wong_m@wustl.edu

Department of Neurology and the Hope Center for Neurological Disorders, Washington University School of Medicine, 660 South Euclid Avenue, Box 8111, St. Louis, MO 63110, USA



© The Author(s). 2019 **Open Access** This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (<http://creativecommons.org/licenses/by/4.0/>), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (<http://creativecommons.org/publicdomain/zero/1.0/>) applies to the data made available in this article, unless otherwise stated.

hyperactivation of the mTOR pathway, which promotes increased cell growth and proliferation and tumor formation. This cellular growth dysregulation leads to the variety of tumors seen in TSC, including subependymal giant cell astrocytomas (SEGA) in the ventricles of the brain, renal angiomyolipomas of the kidneys, lymphangioleiomyomatosis in the lungs, and facial angiofibromas of the skin. mTOR inhibitors are now FDA approved treatments for these brain, kidney, and lung tumors in TSC [8–10] and is also effective against the facial angiofibromas [11]. While mTOR inhibitors, such as rapamycin or everolimus, are clearly effective against different tumor types in TSC, their efficacy against neurological symptoms of TSC is more limited. Adjunctive treatment with everolimus has been shown to have efficacy for focal seizures in TSC patients with drug-resistant epilepsy [12, 13], but the majority of TSC patients continue to have seizures (i.e., do not become seizure-free) and many patients showed minimal benefit from treatment. Furthermore, everolimus was found to have no efficacy against TAND in a battery of neurocognitive and behavioral tests in one recent placebo controlled-trial [14]. Thus, more effective treatments are needed for both TAND and epilepsy in TSC.

Compared with the mechanisms of tumorigenesis in TSC, the pathophysiology of TAND and epilepsy in TSC is poorly understood. Independent of the SEGAs, the classic pathological brain lesion in TSC is the cortical tuber, which gives the disease its name, based on the potato-like appearance on gross pathology. Unlike SEGAs, cortical tubers are focal malformations of cortical development, consisting of localized areas of disrupted cortical lamination and a variety of cellular abnormalities, including astrogliosis, dysmorphic neurons, and giant cells, which are enlarged undifferentiated cells with immature glial and neuronal markers. Cortical tubers are traditionally thought to cause or contribute to neurological manifestations of TSC. There is a correlation between the number of tubers or “tuber load” and the severity of intellectual disability [15]. Furthermore, some studies suggest that the risk of autism may relate to tubers localized to the temporal lobes [16]. However, the correlation between tubers and TAND is non-specific and controversial, not being demonstrated in all studies [17, 18]. There is increasing evidence that cognitive dysfunction and autism are more directly related to tuber-independent abnormalities in the brain, such as disrupted functional connectivity of white matter. There is stronger evidence that epilepsy may be caused by tubers, at least in some cases, as surgical removal of tubers can sometimes eliminate seizures in some TSC patients [19]. However, even when tubers cause seizures, it is still controversial as to whether the seizures start within the tubers themselves or in the surrounding perituberal

region [20, 21]. Regardless of whether seizures start in, around, or independent of tubers, there is increasing evidence that dysregulated cellular and molecular processes also drive epileptogenesis [22]. On the cellular level, while neurons clearly are centrally involved in the brain phenotype of TSC, an attractive novel hypothesis is that abnormalities in glial cells may contribute to the neurological manifestations of TSC (Fig. 1). In this review, we will examine the evidence for different types of glial abnormalities in TSC and their potential role in promoting TAND and epilepsy in TSC.

Main text

Astrocytes

While traditionally astrocytes have been viewed as passive, supportive cells for neurons in the brain, the modern concept of astrocytes entails a more active role in a variety of brain functions [23]. The list of physiological functions of astrocytes continues to grow, including metabolism, structural support, blood-brain barrier maintenance, neurotransmitter regulation and turnover, and direct intercellular communication with other astrocytes and neurons (“gliotransmission”). Astrocytes are critical for maintaining proper energetic balance within the brain, supplying lactate and other nutrients to neurons. Astrocytic processes and endfeet form a component of the blood-brain barrier in conjunction with endothelial cells of the cerebral vasculature. Neurotransmitter transporters on astrocytes, such as for glutamate, absorb glutamate released into synapses by neurons, helping to terminate the synaptic signal and to prevent excitotoxicity. Similarly, astrocytes regulate extracellular potassium homeostasis, which affects neuronal excitability. Perhaps most emblematic of the active role of astrocytes in brain physiology, astrocytes can release gliotransmitters and participate directly in cellular signaling with other astrocytes and neurons through gliotransmission. The diversity of astrocyte functions is paralleled by the heterogeneity of astrocytes, including at least protoplasmic and fibrillary subtypes [24]. Corresponding to the variety of physiological functions in the brain, astrocyte dysfunction can potentially contribute to the pathophysiology of neurological disorders.

The role of astrocytes in TSC was first implicated in pathological brain specimens from TSC patients. Astrogliosis as generally reflected by a change in morphology and increased glial-fibrillary acidic protein (GFAP) staining is a prominent feature of cortical tubers [25–27]. At least two types of morphologically abnormal astrocytes have been described within tubers: “gliotic” astrocytes with elongated radial processes and abundant intermediate filaments and occasional “reactive” astrocytes with increased cell size and vimentin expression often adjacent to giant cells [27]. The cause of astrogliosis in TSC




Fig. 1 Schematic overview of the potential role of glia in the neurological phenotypes of TSC. *TSC1* or *TSC2* gene mutations lead to abnormal hyperactivation of the mechanistic target of rapamycin (mTOR) pathway, which can directly (through cell autonomous effects) or indirectly (through interactions with other cells) cause astrogliosis, microglial activation, and decreased oligodendrocytes. These glial abnormalities can then affect neuronal function through multiple mechanisms, such as impaired glutamate and potassium homeostasis, synaptic remodeling, inflammatory processes, and hypomyelination, which ultimately lead to epilepsy, intellectual disability, autism, and other TSC-associated neuropsychiatric disorders (TAND)

is not known, but could be a primary cell-autonomous effect of *TSC* gene inactivation directly within astrocytes or result secondarily from neuronal abnormalities or seizures that indirectly affect astrocytes. Supporting the former possibility, biochemical evidence of mTOR activation can be detected at least within reactive astrocytes, indicating that the increased cell size is directly caused by *TSC* gene mutation and resulting mTOR hyperactivity [27].

As it is difficult to determine the functional effects of astrocyte abnormalities in human studies, animal models of TSC can more directly examine the role of astrocytes in the pathophysiology of the neurological manifestations of TSC. A variety of knockout or transgenic mouse models of TSC target the brain, involving *Tsc1* or *Tsc2* gene inactivation in different cell types, including both neurons and glia (Table 1). The TSC mouse model that has most extensively investigated astrocytic mechanisms is a conditional knockout mouse, *Tsc1*^{GFAP}CKO mice, in which a glial fibrillary acidic protein (GFAP) promoter has been used to drive *Tsc1* gene inactivation in

astrocytes [28]. On a behavioral level, these mice exhibit cognitive deficits in spatial learning [29], as well as severe epilepsy [30]; thus, *Tsc1*^{GFAP}CKO mice appear to recapitulate some of the key neurological manifestations of TSC.

A number of structural and functional abnormalities have been identified in astrocytes that may contribute to the cognitive deficits and epilepsy in *Tsc1*^{GFAP}CKO mice. On the pathological level, *Tsc1*^{GFAP}CKO mice exhibit widespread astrocyte proliferation due to mTOR hyperactivation, leading to diffuse megalencephaly of the brain [28, 31]. Also directly related to mTOR activation, astrocyte cell size is increased in the *Tsc1*^{GFAP}CKO mice [32]. The specific functional consequences of the increased astrocyte proliferation and size are not entirely clear, but it is reasonable to hypothesize that the gross megalencephaly and disruption of neuronal networks from astroproliferation and astrogliosis could adversely affect neuronal function and excitability, leading to the behavioral deficits and seizures.

Table 1 Mouse models of TSC targeting glia

Mouse Model	Glial pathology	Cognitive			References
		Epilepsy	Deficits	Other/comment	
Astrocytes					
Gfap- <i>Tsc1</i> CKO mice	Astrogliosis/proliferation Increased astrocyte size Impaired glutamate transport, potassium channels, and gap junctions.	+	+	Not specific for astrocytes, some neuronal involvement	[28–36]
Gfap- <i>Tsc2</i> CKO mice	Astrogliosis/proliferation Increased astrocyte size Impaired glutamate transport	+	n/a	Not specific for astrocytes, some neuronal involvement	[37]
Gfap2- <i>Tsc1</i> CKO mice	Astrogliosis/proliferation Decreased myelination	+	n/a	Not specific for astrocytes, some neuronal involvement	[38]
Gfap2- <i>Tsc2</i> CKO mice	Astrogliosis/proliferation Decreased myelination	+	n/a	Not specific for astrocytes, some neuronal involvement	[39, 40]
Inducible GFAP- <i>Tsc1</i> CKO mice	Astrogliosis/proliferation	+/–	n/a	Postnatal <i>Tsc1</i> inactivation more specific for astrocytes	[41]
Microglia					
Cx3cr1- <i>Tsc1</i> CKO mice	Microglia activation Increased microglia size and number.	+	n/a	Controversial as to specificity for microglia	[42, 43]
Inducible Cxcr1- <i>Tsc1</i> CKO mice	Microglia activation Increased microglia size and number	+/–	n/a	Postnatal <i>Tsc1</i> inactivation more specific for microglia	[42, 43]
Oligodendrocytes					
Olig2- <i>Tsc2</i> CKO mice	Hypomyelination Decreased oligodendrocyte number	–	–		[44]

n/a not reported

In addition to these histological and morphological abnormalities, *Tsc1*-knock out astrocytes exhibit a number of molecular defects that interfere with their functional properties. Astrocytes normally contain glutamate transporters, such as glutamate transporter 1 (Glt-1), which remove glutamate from synapses and terminate the synaptic signal. *Tsc1*^{GFAP}CKO mice have decreased Glt-1 expression and a corresponding reduction in astrocyte glutamate transporter function [33], which leads to elevated extracellular glutamate levels and excitotoxic neuronal death [29]. Somewhat paradoxically, excessive synaptic glutamate results in impaired synaptic plasticity of long-term potentiation (LTP), a mechanism of learning and memory [29]. Increased glutamate may logically also promote neuronal hyperexcitability that causes seizures. Thus, astrocyte dysfunction related to glutamate homeostasis may lead to the behavioral learning deficits and epilepsy seen in *Tsc1*^{GFAP}CKO mice.

A number of other astrocyte defects have been found in *Tsc1*^{GFAP}CKO mice, including decreased potassium channel functioning and impaired gap junctions. Similar to glutamate uptake, astrocytes normally play a significant role in buffering extracellular potassium through inward-rectifying potassium channels, which absorb potassium. Networks of astrocytes communicate with each other through gap junctions, which allow redistribution and further buffering of potassium. *Tsc1*^{GFAP}CKO mice have decreased potassium channel expression and a reduction in potassium buffering capability [34, 35]. The decreased potassium buffering by *Tsc1* KO astrocytes

leads to neuronal hyperexcitability, which may promote seizures and cognitive dysfunction.

If astrocyte abnormalities are necessary for the neurological manifestations, treatments that reverse these abnormalities should prevent or improve the neurological symptoms. Ceftriaxone, an antibiotic drug that also increase astrocyte glutamate transporter expression, can reduce seizures in *Tsc1*^{GFAP}CKO mice, providing evidence that impaired astrocyte glutamate transport contributes to the epilepsy phenotype [36]. Furthermore, the mTOR inhibitor, rapamycin reverses the astrocyte proliferation and associated megalencephaly in *Tsc1*^{GFAP}CKO mice and can prevent epilepsy in these mice. Given that GFAP is also expressed in neuroprogenitor cells, the simultaneous contribution of neuronal abnormalities is difficult to rule out in *Tsc1*^{GFAP}CKO mice and the effect of specific *Tsc1* inactivation in astrocytes independent of neurons is more limited [41]. However, overall, these studies suggest that astrocyte abnormalities contribute to epileptogenesis and cognitive dysfunction in *Tsc1*^{GFAP}CKO mice and support novel treatment approaches for neurological manifestations of TSC targeting astrocytes.

Microglia

Microglia represent the resident macrophages of the central nervous system, primarily mediating innate and adaptive immune responses in the brain, such as in reaction to CNS infections, neurodegenerative diseases, or

other brain injury [45]. Microglia differ from other glia in originating outside of the brain from myeloid, rather than neuroectoderm, progenitors, and migrating into the brain during embryogenesis. Microglia may exist in two morphologically and functionally distinct states: a resting and activated state. In their activated state, microglia function to clear cellular debris and produce cytokines and chemokines which coordinate other cellular immune responses from astrocytes, neurons, and lymphocytes. In addition to their central role in immune responses in the brain, microglia have also been found to modulate brain development by regulating neurogenesis, neuronal migration, and synaptic maturation, wiring, and pruning [45]. In contrast to the beneficial functions of microglia, in disease states microglia activation may contribute to pathological processes that are detrimental to the brain.

In TSC, there is pathological evidence of microglial activation within tubers from TSC patients [46, 47]. In cortical tuber specimens resected from TSC patients undergoing epilepsy surgery for intractable epilepsy, prominent activated microglia are identified based on their characteristic morphology and positive staining for markers of microglia activation, HLA-DR and CD68. Microglia are often clustered around dysmorphic neurons and giant cells and are also associated with other immune mediators, including CD8-positive T lymphocytes and components of the complement cascade. These pathological findings suggest that microglia can play a role in the pathophysiology of neurological manifestations of TSC. However, as seizures themselves may cause microglia activation [48], it is difficult to determine whether the microglia activation in tuber specimens from TSC patients with epilepsy is a primary pathophysiological mechanism or is simply secondary to seizures.

Although it is not clear to what degree *TSC* gene inactivation and associated mTOR hyperactivation occur directly in microglia in the human pathological studies, targeted *Tsc* gene inactivation in mouse models can help address the question of whether microglia abnormalities may play a primary role in the pathogenesis of TSC. First of all, *Tsc1*^{GFAP}CKO mice exhibit elevated Iba1 staining, a marker of microglia activation, and increased microglia size and number [49]. Minocycline, a drug that can inhibit microglia activation, is able to prevent the morphological changes in microglia, but has no effect on seizures, suggesting that the microglia activation is a secondary effect that does not cause epilepsy in *Tsc1*^{GFAP}CKO mice. This result is perhaps not surprising, given that GFAP-driven *Tsc1* inactivation is expected to affect astrocytes and neurons, but not microglia directly.

Recent studies have attempted to inactivate *Tsc* genes directly in microglia, such as using a Cx3 chemokine

receptor 1 (Cx3cr1) driver, which is a chemokine receptor that is traditionally thought to be specifically expressed in microglia. *Tsc1*^{Cx3Cr1}CKO mice exhibit mTOR hyperactivation in microglia and resulting increased microglia size and number, indicating that *Tsc1* inactivation has cell autonomous effects in microglia [42, 43]. *Tsc1*^{Cx3Cr1}CKO mice have severe epilepsy, as well as megalencephaly, reduced synaptic density, and neuronal degeneration, although a neurocognitive or behavioral phenotype has not been reported. This suggests that intrinsic microglia abnormalities may be sufficient to at least cause epilepsy in TSC. However, there is some controversy as to the specificity of *Tsc1* inactivation in *Tsc1*^{Cx3Cr1}CKO mice, which may not be limited to microglia but likely also affects neurons, and whether more specific postnatal *Tsc1* inactivation in microglia causes epilepsy [42]. Thus, microglia may contribute to or modulate the neurological manifestations of TSC, but might also require concurrent neuronal abnormalities. Future animal model studies with more selective targeting of microglia may help resolve the specific role of microglia in epilepsy in TSC more definitively, as well as examine their effects on cognitive function.

Oligodendrocytes

Oligodendrocytes are the third major type of glia cell in the central nervous system and are most directly involved in development and maintenance of the white matter of the brain [50]. Akin to Schwann cells in the peripheral nervous system, the primary function of oligodendrocytes is to form the myelin insulation of axons, allowing for efficient and rapid conduction of action potential signaling along white matter tracts between brain regions. Oligodendrocytes and myelin exhibit significant heterogeneity and are not uniformly distributed throughout the brain, suggesting that oligodendrocytes play a differential role in regulating brain function and neuronal networks [51, 52]. Dysfunction or degeneration of oligodendrocytes are the cardinal feature of demyelinating or dysmyelinating diseases, such as multiple sclerosis, which often feature cognitive impairment, in addition to more classic focal neurological deficits.

Although cortical tubers have classically been the pathological hallmark of the neurological phenotype of TSC, white matter abnormalities have emerged as an equally important and distinctive mechanism for brain dysfunction in TSC. Pathological studies have found decreased myelin content and oligodendrocyte number in and around cortical tuber specimens [53]. This decrease in myelin and oligodendrocytes within tubers has been linked to a deficiency in oligodendrocyte progenitor cells and elevated mTOR activity [53], suggesting that TSC

involves a primary defect in oligodendrocytes related to *TSC* gene inactivation.

A plethora of MRI studies have further documented abnormalities in white matter that are much more extensive and diffuse than just tubers. In particular, diffusion tensor imaging (DTI) has been used to evaluate microstructural changes in white matter, based on the general principle that water diffusion in normal white matter is directionally restricted primarily to parallel to the orientation of axons (anisotropy), whereas disruption of the normal organization of white matter leads to increased diffusion in other directions. Multiple MRI studies using DTI have documented increased mean diffusivity and decreased anisotropy in white matter of *TSC* patients in the corpus callosum, subcortical white matter, internal capsule, and other white matter tracts that appear grossly normal on MRI and are remote from tubers [54–56], indicating disruption in microstructural organization and abnormal myelination of white matter in *TSC*.

In terms of the functional significance of these white matter abnormalities, *TSC* patients with autism spectrum disorder have more severe abnormalities in DTI parameters compared with *TSC* patients without ASD and control patients, whereas there is no significant difference between *TSC* patient without ASD and controls [57]. When examining white matter pathways involved in language processing, particularly the arcuate fasciculus, *TSC* patients with ASD have abnormalities in diffusivity and anisotropy compared with *TSC* patients without ASD, although there are also additional differences between *TSC* patients without ASD and controls [58]. These white matter abnormalities are associated with an overall decrease in measures of functional connectivity between different regions of the brain, including reduced interhemispheric synchrony [59]. Furthermore, the degree of white matter abnormalities is also correlated with the presence of seizures [60]. Overall, epilepsy, intellectual disability, and ASD individually seem to have additive effects on the abnormal DTI measures [61].

From a therapeutic standpoint, an important question is whether these white matter abnormalities may be reversible. Interestingly, the mTOR inhibitor everolimus produces decreases in diffusivity and increases in anisotropy in serial DTI studies of *TSC* patients [62]. Longitudinal studies have found that longer periods of treatment with everolimus results in greater effects [63]. The mechanism of this effect of everolimus on these DTI parameters is not known, but could be related directly to structural or metabolic effects on oligodendrocytes or axons, such as decreases in extracellular fluid or cellular volume and improved myelination or myelin leakiness, or indirectly to a decrease in seizures. In any case, these exciting findings suggest that white matter

abnormalities in *TSC* can be reversed by treatment, which provides a potential mechanistic avenue for therapeutic interventions for cognitive dysfunction and ASD in *TSC* patients.

Animal models and other reduced systems have delved further into the mechanistic basis of white matter abnormalities in *TSC*, which could result either from cell autonomous effects of *TSC* gene inactivation in oligodendrocytes or abnormal signaling from *TSC*-deficient neurons or astrocytes that indirectly affect oligodendrocytes. Inactivation of *Tsc2* directly in oligodendrocytes in mice using a *Olig2* promoter leads to a marked hypomyelination phenotype, supporting a cell autonomous effect of oligodendrocytes directly [44]. This hypomyelination is related to decreased oligodendrocyte number from a shift in oligodendrocyte precursor differentiation from oligodendrocytes to astrocytes, as well as to decreased myelin thickness. In addition, mice with neuron-specific inactivation of *Tsc1* also demonstrate a hypomyelination phenotype, supporting that abnormal communication from neurons to oligodendrocytes can cause white matter abnormalities [64]. This neuronal regulation of oligodendrocyte-mediated myelination is mediated by connective tissue growth factor secreted by neurons, which then negatively regulates oligodendrocyte development [65]. Conversely, *TSC*-deficient oligodendrocytes, derived from human induced pluripotent stem cells (iPSCs) from *TSC* patients, can affect the morphological and physiological properties of neurons, suggesting a bi-directional regulation between oligodendrocytes and neurons [66]. So, overall, there is evidence of both cell-autonomous effects of oligodendrocytes and interactions between neurons and oligodendrocytes in causing white matter abnormalities in *TSC*.

Conclusions and future directions

Glia cells of different types have emerged as major players in causing or contributing to TAND and other neurological phenotypes of the genetic disorder, *TSC*. While neurons remain the cardinal cell of the brain directly mediating neurological manifestations, both cell autonomous actions of glia and interactions of glia and neurons appear critical for a variety of brain symptoms of *TSC*, including intellectual disability, autism, epilepsy, and other psychiatric and behavioral disorders. However, there are a number of outstanding issues that need to be resolved in further defining the role of glia in *TSC*.

As neurons and glia work together in complex, inter-dependent networks, it is difficult to isolate and disentangle the relative contribution and role of glia in neurological manifestations. Knockout mice specifically targeting glia cells have clearly established cell autonomous effects of *Tsc* gene inactivation directly within glia. However, proving that these effects by themselves are sufficient to cause neurological manifestations or are co-dependent on *Tsc* gene inactivation in neurons has been difficult. In addition, it is

not clearly resolved whether germline mutation of a single TSC allele in the heterozygous state is sufficient to cause neurological symptoms or a “second hit” involving an additional somatic mutation and resulting in a homozygous mutant state is required, especially in the human disease. Simplified systems, such as induced pluripotent stem cell (iPSC)-derived neurons and glia, can be utilized to better address these questions of cell-autonomous versus interdependent effects and heterozygous versus homozygous states.

Another long-standing controversy within the TSC field is the role of tubers in causing neurological manifestations. Tubers have traditionally been thought of as being the critical pathological substrate, with tubers directly causing seizures and with tuber load correlating with intellectual disability and autism. However, microstructural defects in non-tuber parts of the brain have received increasing attention as contributing to the neurological phenotype of TSC. Glial cells, in particular, provide an obvious cellular platform for mediating brain dysfunction independent of gross structural lesions, such as in the case of oligodendrocytes and white matter abnormalities in TSC. Ultimately, there may be a continuum of glial defects between tubers, perituberal regions, and remote structurally “normal” areas of the brain. Increasingly sophisticated imaging studies examining brain connectivity and correlating with pathological and neurophysiological parameters can further determine the interrelationship between tuber and non-tuber areas of the brain in causing neurological manifestations of TSC in general, as well as in relation to glia.

The wide range of neurological symptoms of TSC, encompassed by the term TAND, as well as epilepsy, raises mechanistic and therapeutic questions as to the causal or correlative relationship between different symptoms. In particular, do overlapping networks and cellular elements cause diverse neurological manifestations or are there independent, distinctive mechanisms for each symptom? Furthermore, do some manifestations, particularly seizures, directly exacerbate other symptoms, such as intellectual disability? Again, omnipresent, highly interconnected glial cells throughout the brain represent a natural substrate for mediating interactions between the different neurological phenotypes of TSC. Understanding and targeting these overlapping glial features may provide opportunities for therapeutic interventions that simultaneously and synergistically benefit multiple neurological manifestations of TSC.

Finally, glial cells do represent a potential novel therapeutic target for neurological symptoms of TSC. Current treatments for epilepsy primarily regulate neuronal mechanisms, such as by directly controlling neuronal excitability via modulation of ion channels or neurotransmitter systems, and there are essentially no specific

pharmacological treatments for most of the manifestations of TAND. One of the major limitations of current neuroactive medications is sedation and cognitive slowing due to depression of normal neuronal activity. Targeting glial cells has the potential to modulate neuronal networks without directly causing neuronal depression. While the emergence of mTOR inhibitors as a treatment for TSC has revolutionized the targeted therapeutic approach to TSC in general, limitations in efficacy for neurological symptoms of TSC and systemic side effects of mTOR inhibitors indicate that additional directed strategies to treating neurological manifestations of TSC. Given the prevalence of glial abnormalities in TSC, TSC has the potential to be a model disease for investigating and targeting glia as novel therapeutic approaches to neurodevelopmental disorders in general.

Abbreviations

ASD: Autism spectrum disorder; Cx3cr1: Cx3 chemokine receptor 1; DTI: Diffusion tensor imaging; FDA: Food and Drug Administration; GFAP: Glial fibrillary acidic protein; Glt-1: Glutamate transporter 1; iPSCs: Induced pluripotent stem cells; LTP: Long-term potentiation; mTOR: Mechanistic target of rapamycin; SEGA: Subependymal giant cell astrocytoma; TAND: TSC-associated neuropsychiatric disorders; TSC: Tuberous sclerosis complex; *Tsc1*^{GFAP}CKO mice: *Tsc1*-GFAP conditional knockout mice

Acknowledgements

n/a

Author's contribution

MW conceptualized and wrote the manuscript. The author read and approved the final manuscript.

Funding

This work was supported by the National Institutes of Health (R01 NS056872 to MW), the McDonnell Center for Cellular and Molecular Neurobiology, and the Intellectual and Developmental Disabilities Research Center (U54 HD087011) at Washington University.

Availability of data and materials

n/a

Ethics approval and consent to participate

n/a

Consent for publication

n/a

Competing interests

The author declares that he has no competing interests.

Received: 3 January 2019 Accepted: 11 November 2019

Published online: 16 December 2019

References

1. Crino PB, Nathanson KL, Henske EP. The tuberous sclerosis complex. *N Engl J Med*. 2006;355:1345–56.
2. Orlova KA, Crino PB. The tuberous sclerosis complex. *Ann N Y Acad Sci*. 2010;1184:87–105.
3. de Vries PJ, Belousova E, Benedik MP, Carter T, Cottin V, Curatolo P, Dahlin M, D'Amato L, d'Augeres GB, Ferreira JC, et al. TSC-associated neuropsychiatric disorders (TAND): findings from the TOSCA natural history study. *Orphanet J Rare Dis*. 2018;13:157.
4. de Vries PJ, Wilde L, de Vries MC, Moavero R, Pearson DA, Curatolo P. A clinical update on tuberous sclerosis complex-associated neuropsychiatric disorders (TAND). *Am J Med Genet C Semin Med Genet*. 2018;178:309–20.

5. Chu-Shore CJ, Major P, Camposano S, Muzykewicz D, Thiele EA. The natural history of epilepsy in tuberous sclerosis complex. *Epilepsia*. 2010;51:1236–41.
6. Saxton RA, Sabatini DM. mTOR signaling in growth, metabolism, and disease. *Cell*. 2017;168:960–76.
7. Lipton JO, Sahin M. The neurology of mTOR. *Neuron*. 2014;84:275–91.
8. Krueger DA, Care MM, Holland K, Agricola K, Tudor C, Mangeshkar P, Wilson KA, Byars A, Sahmoud T, Franz DN. Everolimus for subependymal giant-cell astrocytomas in tuberous sclerosis. *N Engl J Med*. 2010;363:1801–11.
9. Franz DN, Belousova E, Sparagana S, Bebin EM, Frost M, Kuperman R, Witt O, Kohrman MH, Flamini JR, Wu JY, et al. Efficacy and safety of everolimus for subependymal giant cell astrocytomas associated with tuberous sclerosis complex (EXIST-1): a multicentre, randomised, placebo-controlled phase 3 trial. *Lancet*. 2013;381:125–32.
10. Bissler JJ, Kingswood JC, Radzikowska E, Zonnenberg BA, Frost M, Belousova E, Sauter M, Nonomura N, Brakemeier S, de Vries PJ, et al. Everolimus for angiolymphangioma associated with tuberous sclerosis complex or sporadic lymphangiomyomatosis (EXIST-2): a multicentre, randomised, double-blind, placebo-controlled trial. *Lancet*. 2013;381:817–24.
11. Koenig MK, Bell CS, Hebert AA, Roberson J, Samuels JA, Slopis JM, Tate P, Northrup H. Efficacy and safety of topical rapamycin in patients with facial angiofibromas secondary to tuberous sclerosis complex: the TREATMENT randomized clinical trial. *JAMA Dermatol*. 2018;154:773–80.
12. French JA, Lawson JA, Yapici Z, Ikeda H, Polster T, Nabbout R, Curatolo P, de Vries PJ, Dlugos DJ, Berkowitz N, et al. Adjunctive everolimus therapy for treatment-resistant focal-onset seizures associated with tuberous sclerosis (EXIST-3): a phase 3, randomised, double-blind, placebo-controlled study. *Lancet*. 2016;388:2153–63.
13. Krueger DA, Wilfong AA, Holland-Bouley K, Anderson AE, Agricola K, Tudor C, Mays M, Lopez CM, Kim MO, Franz DN. Everolimus treatment of refractory epilepsy in tuberous sclerosis complex. *Ann Neurol*. 2013;74:679–87.
14. Krueger DA, Sadhwani A, Byars AW, de Vries PJ, Franz DN, Whittemore VH, Filip-Dhima R, Murray D, Kapur K, Sahin M. Everolimus for treatment of tuberous sclerosis complex-associated neuropsychiatric disorders. *Ann Clin Transl Neurol*. 2017;4:877–87.
15. Goodman M, Lamm SH, Engel A, Shepherd CW, Houser OW, Gomez MR. Cortical tuber count: a biomarker indicating neurologic severity of tuberous sclerosis complex. *J Child Neurol*. 1997;12:85–90.
16. Bolton PF, Griffiths PD. Association of tuberous sclerosis of temporal lobes with autism and atypical autism. *Lancet*. 1997;349:392–5.
17. Kaczorowska M, Jurkiewicz E, Domanska-Pakiela D, Syczewska M, Lojczyk B, Chmielewski D, Kotulska K, Kuczynski D, Kmiec T, Dunin-Wasowicz D, et al. Cerebral tuber count and its impact on mental outcome of patients with tuberous sclerosis complex. *Epilepsia*. 2011;52:22–7.
18. Walz NC, Byars AW, Egelhoff JC, Franz DN. Supratentorial tuber location and autism in tuberous sclerosis complex. *J Child Neurol*. 2002;17:830–2.
19. Bollo RJ, Kalhorn SP, Carlson C, Haegeli V, Devinsky O, Weiner HL. Epilepsy surgery and tuberous sclerosis complex: special considerations. *Neurosurg Focus*. 2008;25:E13.
20. Major P, Rakowski S, Simon MV, Cheng ML, Eskandar E, Baron J, Leeman BA, Frosch MP, Thiele EA. Are cortical tubers epileptogenic? Evidence from electrocorticography. *Epilepsia*. 2009;50:147–54.
21. Kannan L, Vogrin S, Bailey C, Maixner W, Harvey AS. Centre of epileptogenic tubers generate and propagate seizures in tuberous sclerosis. *Brain*. 2016;139:2653–67.
22. Wong M. Mechanisms of epileptogenesis in tuberous sclerosis complex and related malformations of cortical development with abnormal glioneuronal proliferation. *Epilepsia*. 2008;49:8–21.
23. Ransom B, Behar T, Nedergaard M. New roles for astrocytes (stars at last). *Trends Neurosci*. 2003;26:520–2.
24. Schitine C, Nogaroli L, Costa MR, Hedin-Pereira C. Astrocyte heterogeneity in the brain: from development to disease. *Front Cell Neurosci*. 2015;9:76.
25. Trombley IK, Mirra SS. Ultrastructure of tuberous sclerosis: cortical tuber and subependymal tumor. *Ann Neurol*. 1981;9:174–81.
26. Stefansson K, Wollmann R. Distribution of glial fibrillary acidic protein in central nervous system lesions of tuberous sclerosis. *Acta Neuropathol*. 1980;52:135–40.
27. Sosunov AA, Wu X, McGovern RA, Coughlin DG, Mikell CB, Goodman RR, McKhann GM 2nd. The mTOR pathway is activated in glial cells in mesial temporal sclerosis. *Epilepsia*. 2012;53(Suppl 1):78–86.
28. Uhlmann EJ, Wong M, Baldwin RL, Bajenaru ML, Onda H, Kwiatkowski DJ, Yamada K, Gutmann DH. Astrocyte-specific TSC1 conditional knockout mice exhibit abnormal neuronal organization and seizures. *Ann Neurol*. 2002;52:285–96.
29. Zeng LH, Ouyang Y, Gazit V, Cirrito JR, Jansen LA, Ess KC, Yamada KA, Wozniak DF, Holtzman DM, Gutmann DH, Wong M. Abnormal glutamate homeostasis and impaired synaptic plasticity and learning in a mouse model of tuberous sclerosis complex. *Neurobiol Dis*. 2007;28:184–96.
30. Erbayat-Altay E, Zeng LH, Xu L, Gutmann DH, Wong M. The natural history and treatment of epilepsy in a murine model of tuberous sclerosis. *Epilepsia*. 2007;48:1470–6.
31. Zeng LH, Xu L, Gutmann DH, Wong M. Rapamycin prevents epilepsy in a mouse model of tuberous sclerosis complex. *Ann Neurol*. 2008;63:444–53.
32. Uhlmann EJ, Li W, Scheidenhelm DK, Gau CL, Tamanoi F, Gutmann DH. Loss of tuberous sclerosis complex 1 (Tsc1) expression results in increased Rheb/S6K pathway signaling important for astrocyte cell size regulation. *Glia*. 2004;47:180–8.
33. Wong M, Ess KC, Uhlmann EJ, Jansen LA, Li W, Crino PB, Mennerick S, Yamada KA, Gutmann DH. Impaired glial glutamate transport in a mouse tuberous sclerosis epilepsy model. *Ann Neurol*. 2003;54:251–6.
34. Jansen LA, Uhlmann EJ, Crino PB, Gutmann DH, Wong M. Epileptogenesis and reduced inward rectifier potassium current in tuberous sclerosis complex-1-deficient astrocytes. *Epilepsia*. 2005;46:1871–80.
35. Xu L, Zeng LH, Wong M. Impaired astrocytic gap junction coupling and potassium buffering in a mouse model of tuberous sclerosis complex. *Neurobiol Dis*. 2009;34:291–9.
36. Zeng LH, Bero AW, Zhang B, Holtzman DM, Wong M. Modulation of astrocyte glutamate transporters decreases seizures in a mouse model of tuberous sclerosis complex. *Neurobiol Dis*. 2010;37:764–71.
37. Zeng LH, Rensing NR, Zhang B, Gutmann DH, Gambello MJ, Wong M. Tsc2 gene inactivation causes a more severe epilepsy phenotype than Tsc1 inactivation in a mouse model of tuberous sclerosis complex. *Hum Mol Genet*. 2011;20:445–54.
38. Magri L, Cominelli M, Cambiaghi M, Cursi M, Leocani L, Minicucci F, Poliani PL, Galli R. Timing of mTOR activation affects tuberous sclerosis complex neuropathology in mouse models. *Dis Model Mech*. 2013;6:1185–97.
39. Way SW, McKenna J 3rd, Mietzsch U, Reith RM, Wu HC, Gambello MJ. Loss of Tsc2 in radial glia models the brain pathology of tuberous sclerosis complex in the mouse. *Hum Mol Genet*. 2009;18:1252–65.
40. Way SW, Rozas NS, Wu HC, McKenna J 3rd, Reith RM, Hashmi SS, Dash PK, Gambello MJ. The differential effects of prenatal and/or postnatal rapamycin on neurodevelopmental defects and cognition in a neuroglial mouse model of tuberous sclerosis complex. *Hum Mol Genet*. 2012;21:3226–36.
41. Zou J, Zhang B, Gutmann DH, Wong M. Postnatal reduction of tuberous sclerosis complex 1 expression in astrocytes and neurons causes seizures in an age-dependent manner. *Epilepsia*. 2017;58:2053–63.
42. Zhang B, Zou J, Han L, Beeler B, Friedman JL, Griffin E, Piao YS, Rensing NR, Wong M. The specificity and role of microglia in epileptogenesis in mouse models of tuberous sclerosis complex. *Epilepsia*. 2018;59:1796–806.
43. Zhao X, Liao Y, Morgan S, Mathur R, Feustel P, Mazurkiewicz J, Qian J, Chang J, Mathern GW, Adamo MA, et al. Noninflammatory changes of microglia are sufficient to cause epilepsy. *Cell Rep*. 2018;22:2080–93.
44. Carson RP, Kelm ND, West KL, Does MD, Fu C, Weaver G, McBrier E, Parker B, Grier MD, Ess KC. Hypomyelination following deletion of Tsc2 in oligodendrocyte precursors. *Ann Clin Transl Neurol*. 2015;2:1041–54.
45. Schafer DP, Stevens B. Microglia function in central nervous system development and plasticity. *Cold Spring Harb Perspect Biol*. 2015;7:a020545.
46. Boer K, Jansen F, Nellist M, Redeker S, van den Ouweland AM, Spliet WG, van Nieuwenhuizen O, Troost D, Crino PB, Aronica E. Inflammatory processes in cortical tubers and subependymal giant cell tumors of tuberous sclerosis complex. *Epilepsy Res*. 2008;78:7–21.
47. Boer K, Troost D, Jansen F, Nellist M, van den Ouweland AM, Geurts JJ, Spliet WG, Crino P, Aronica E. Clinicopathological and immunohistochemical findings in an autopsy case of tuberous sclerosis complex. *Neuropathology*. 2008;28:577–90.
48. Shapiro LA, Wang L, Ribak CE. Rapid astrocyte and microglial activation following pilocarpine-induced seizures in rats. *Epilepsia*. 2008;49(Suppl 2):33–41.
49. Zhang B, Zou J, Han L, Rensing N, Wong M. Microglial activation during epileptogenesis in a mouse model of tuberous sclerosis complex. *Epilepsia*. 2016;57:1317–25.
50. Bradl M, Lassmann H. Oligodendrocytes: biology and pathology. *Acta Neuropathol*. 2010;119:37–53.

51. Dimou L, Simons M. Diversity of oligodendrocytes and their progenitors. *Curr Opin Neurobiol*. 2017;47:73–9.
52. de Hoz L, Simons M. The emerging functions of oligodendrocytes in regulating neuronal network behaviour. *Bioessays*. 2015;37:60–9.
53. Scholl T, Muhlechner A, Ricken G, Gruber V, Fabing A, Samuelli S, Groppe G, Dorfer C, Czech T, Hainfellner JA, et al. Impaired oligodendroglial turnover is associated with myelin pathology in focal cortical dysplasia and tuberous sclerosis complex. *Brain Pathol*. 2017;27:770–80.
54. Garaci FG, Floris R, Bozzao A, Manenti G, Simonetti A, Lupattelli T, Curatolo P, Simonetti G. Increased brain apparent diffusion coefficient in tuberous sclerosis. *Radiology*. 2004;232:461–5.
55. Makki MI, Chugani DC, Janisse J, Chugani HT. Characteristics of abnormal diffusivity in normal-appearing white matter investigated with diffusion tensor MR imaging in tuberous sclerosis complex. *AJNR Am J Neuroradiol*. 2007;28:1662–7.
56. Krishnan ML, Commowick O, Jeste SS, Weisenfeld N, Hans A, Gregas MC, Sahin M, Warfield SK. Diffusion features of white matter in tuberous sclerosis with tractography. *Pediatr Neurol*. 2010;42:101–6.
57. Peters JM, Sahin M, Vogel-Farley VK, Jeste SS, Nelson CA 3rd, Gregas MC, Prabhu SP, Scherrer B, Warfield SK. Loss of white matter microstructural integrity is associated with adverse neurological outcome in tuberous sclerosis complex. *Acad Radiol*. 2012;19:17–25.
58. Lewis WW, Sahin M, Scherrer B, Peters JM, Suarez RO, Vogel-Farley VK, Jeste SS, Gregas MC, Prabhu SP, Nelson CA 3rd, Warfield SK. Impaired language pathways in tuberous sclerosis complex patients with autism spectrum disorders. *Cereb Cortex*. 2013;23:1526–32.
59. Im K, Ahtam B, Haehn D, Peters JM, Warfield SK, Sahin M, Ellen Grant P. Altered structural brain networks in tuberous sclerosis complex. *Cereb Cortex*. 2016;26:2046–58.
60. Moavero R, Napolitano A, Cusmai R, Vigevaro F, Figa-Talamanca L, Calbi G, Curatolo P, Bernardi B. White matter disruption is associated with persistent seizures in tuberous sclerosis complex. *Epilepsy Behav*. 2016;60:63–7.
61. Baumer FM, Peters JM, Clancy S, Prohl AK, Prabhu SP, Scherrer B, Jansen FE, Braun KPJ, Sahin M, Stamm A, Warfield SK. Corpus callosum white matter diffusivity reflects cumulative neurological comorbidity in tuberous sclerosis complex. *Cereb Cortex*. 2018;28:3665–72.
62. Tillema JM, Leach JL, Krueger DA, Franz DN. Everolimus alters white matter diffusion in tuberous sclerosis complex. *Neurology*. 2012;78:526–31.
63. Peters JM, Prohl A, Kapur K, Nath A, Scherrer B, Clancy S, Prabhu SP, Sahin M, Franz DN, Warfield SK, Krueger DA. Longitudinal effects of everolimus on white matter diffusion in tuberous sclerosis complex. *Pediatr Neurol*. 2019; 90:24–30.
64. Meikle L, Talos DM, Onda H, Polizzi K, Rotenberg A, Sahin M, Jensen FE, Kwiatkowski DJ. A mouse model of tuberous sclerosis: neuronal loss of Tsc1 causes dysplastic and ectopic neurons, reduced myelination, seizure activity, and limited survival. *J Neurosci*. 2007;27:5546–58.
65. Ercan E, Han JM, Di Nardo A, Winden K, Han MJ, Hoyo L, Saffari A, Leask A, Geschwind DH, Sahin M. Neuronal CTGF/CCN2 negatively regulates myelination in a mouse model of tuberous sclerosis complex. *J Exp Med*. 2017;214:681–97.
66. Nadadhur AG, Alsaqati M, Gasparotto L, Cornelissen-Steijger P, van Hughte E, Dooves S, Harwood AJ, Heine VM. Neuron-glia interactions increase neuronal phenotypes in tuberous sclerosis complex patient iPSC-derived models. *Stem Cell Reports*. 2018;12:42–56.

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Ready to submit your research? Choose BMC and benefit from:

- fast, convenient online submission
- thorough peer review by experienced researchers in your field
- rapid publication on acceptance
- support for research data, including large and complex data types
- gold Open Access which fosters wider collaboration and increased citations
- maximum visibility for your research: over 100M website views per year

At BMC, research is always in progress.

Learn more biomedcentral.com/submissions

